Wei Shi

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 505 citations

Medicine, Oncology, Pharmacology +13

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

Medicine, Oncology, Pharmacology +6

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Yun Fan, Jun Zhao, Qiming Wang et al. · Journal of Thoracic Oncology · 2020 · 139 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Klebsiella pneumoniae induces host metabolic stress that promotes tolerance to pulmonary infection

Tania Wong Fok Lung, Daniel Charytonowicz, Kristin G. Beaumont et al. · Cell Metabolism · 2022 · 104 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17